Artykuły w czasopismach na temat „IRINOTECAN CANCER TREATMENT”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „IRINOTECAN CANCER TREATMENT”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa i in. "The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer." Journal of Clinical Oncology 37, nr 4_suppl (1.02.2019): 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.
Pełny tekst źródłaFalcone, Alfredo, Antonello Di Paolo, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Monica Lencioni, Elisabetta Pfanner, Silvia Comis, Mario Del Tacca i Pierfranco Conte. "Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients". Journal of Clinical Oncology 19, nr 15 (1.08.2001): 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.
Pełny tekst źródłaVanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber i Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview". Journal of Clinical Oncology 19, nr 5 (1.03.2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.
Pełny tekst źródłaBailly, Christian. "Irinotecan: 25 years of cancer treatment". Pharmacological Research 148 (październik 2019): 104398. http://dx.doi.org/10.1016/j.phrs.2019.104398.
Pełny tekst źródłaKockaya, Guvenc, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz i Saim Kerman. "Treatment cost of metastatic colon cancer in Turkey". Farmeconomia. Health economics and therapeutic pathways 14, nr 1 (30.01.2013): 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.
Pełny tekst źródłaRadajewska, Anna, Helena Moreira, Dorota Bęben, Oliwia Siwiela, Anna Szyjka, Katarzyna Gębczak, Paulina Nowak i in. "Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment". International Journal of Molecular Sciences 24, nr 11 (31.05.2023): 9544. http://dx.doi.org/10.3390/ijms24119544.
Pełny tekst źródłaAoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma i in. "Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer". ESMO Open 4, nr 3 (maj 2019): e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.
Pełny tekst źródłaKciuk, Mateusz, Beata Marciniak i Renata Kontek. "Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview". International Journal of Molecular Sciences 21, nr 14 (12.07.2020): 4919. http://dx.doi.org/10.3390/ijms21144919.
Pełny tekst źródłaSagawa, Tamotsu, Hironaga Satake, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato i Akihito Tsuji. "Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 155. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.155.
Pełny tekst źródłaShun, Yu-Ting, Hsien-Yung Lai, Yi-Ting Chuang i Hsuen-Fu Lin. "Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report". Clinical Medicine Insights: Case Reports 16 (styczeń 2023): 117954762211503. http://dx.doi.org/10.1177/11795476221150354.
Pełny tekst źródłaHulshof, Emma C., Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit ALM Deiman, Jesse J. Swen, Saskia Houterman i in. "Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 3574. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3574.
Pełny tekst źródłaJahan, Zeenat, Fahad A. Benthani, Nicola Currey, Hannah W. Parker, Jane E. Dahlstrom, C. Elizabeth Caldon i Maija R. J. Kohonen-Corish. "MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib". Cancers 14, nr 12 (9.06.2022): 2859. http://dx.doi.org/10.3390/cancers14122859.
Pełny tekst źródłaBugat, R. "Irinotecan in the treatment of gastric cancer". Annals of Oncology 14 (czerwiec 2003): ii37—ii40. http://dx.doi.org/10.1093/annonc/mdg727.
Pełny tekst źródłaWilke, H., O. Bouché, P. Rougier i C. H. Köhne. "Irinotecan for the treatment of gastric cancer". European Journal of Cancer Supplements 2, nr 7 (czerwiec 2004): 48–51. http://dx.doi.org/10.1016/j.ejcsup.2004.04.015.
Pełny tekst źródłaFuchs, Charles, Edith P. Mitchell i Paulo M. Hoff. "Irinotecan in the treatment of colorectal cancer". Cancer Treatment Reviews 32, nr 7 (listopad 2006): 491–503. http://dx.doi.org/10.1016/j.ctrv.2006.07.001.
Pełny tekst źródłaSobrero, Alberto F., Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas i in. "EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology 26, nr 14 (10.05.2008): 2311–19. http://dx.doi.org/10.1200/jco.2007.13.1193.
Pełny tekst źródłaWang, Wenjie, Monica Rodriguez-Silva, Arlet M. Acanda de la Rocha, Aizik L. Wolf, Yanhao Lai, Yuan Liu, William C. Reinhold, Yves Pommier, Jeremy W. Chambers i Yuk-Ching Tse-Dinh. "Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents". Cancers 11, nr 10 (23.09.2019): 1416. http://dx.doi.org/10.3390/cancers11101416.
Pełny tekst źródłaGiuliani, F., i G. Colucci. "Cetuximab in Colon Cancer". International Journal of Biological Markers 22, nr 1_suppl4 (styczeń 2007): 62–70. http://dx.doi.org/10.1177/17246008070221s408.
Pełny tekst źródłaHironaka, Shuichi, Shinya Ueda, Hirofumi Yasui, Tomohiro Nishina, Masahiro Tsuda, Takehiko Tsumura, Naotoshi Sugimoto i in. "Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial". Journal of Clinical Oncology 31, nr 35 (10.12.2013): 4438–44. http://dx.doi.org/10.1200/jco.2012.48.5805.
Pełny tekst źródłaStrock, Christopher J., Jong-In Park, D. Marc Rosen, Bruce Ruggeri, Samuel R. Denmeade, Douglas W. Ball i Barry D. Nelkin. "Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer". Journal of Clinical Endocrinology & Metabolism 91, nr 1 (1.01.2006): 79–84. http://dx.doi.org/10.1210/jc.2005-1882.
Pełny tekst źródłaO'Reilly, Eileen Mary, Andy Surinach, Allison Dillon, Paul Cockrum i Kenneth H. Yu. "Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients." Journal of Clinical Oncology 38, nr 4_suppl (1.02.2020): 667. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.667.
Pełny tekst źródłaCunningham, Julia Marie, Petra Prins, Brian Conkright, Simina Boca, Shruti Rao, Andrew Gabrielson, Andrew Oseran i in. "Molecular profiling of TOPO1: A way to evaluate irinotecan treatment in colorectal cancer?" Journal of Clinical Oncology 34, nr 4_suppl (1.02.2016): 546. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.546.
Pełny tekst źródłaAmonkar, Mayur, David Gomez-Ulloa, Smita Kothari, Winson Y. Cheung, Ian Chau, John Raymond Zalcberg, Nuria Lara i Alfredo Falcone. "Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC)." Journal of Clinical Oncology 37, nr 4_suppl (1.02.2019): 102. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.102.
Pełny tekst źródłaMir, Tanveer Ahmad, Ahmed S. Yassin, Eric Joseph Denha, Raad Al Shaikhli, Ali Rahim, Sabah Ambreen i Prateek Lohia. "Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer". BMJ Case Reports 13, nr 5 (maj 2020): e232053. http://dx.doi.org/10.1136/bcr-2019-232053.
Pełny tekst źródłaKim, Seong-Ryong, Hyun Jung Lee i Dalyong Kim. "Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report". Case Reports in Oncology 14, nr 3 (30.12.2021): 1882–88. http://dx.doi.org/10.1159/000521315.
Pełny tekst źródłaJang, Hyun Joo, Eun Mi Hong, Juah Jang, Jung Eun Choi, Se Woo Park, Hyun Woo Byun, Dong Hee Koh, Min Ho Choi, Sea Hyub Kae i Jin Lee. "Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance". Gastroenterology Research and Practice 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/7891374.
Pełny tekst źródłaGonzalez-Baron, M., M. Blanco, J. Feliu, C. Gómez, E. Casado, J. Castro, C. Belda-Iniesta, M. Garrido, C. Aguayo i M. A. Campos. "Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 14600. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14600.
Pełny tekst źródłaLim, Sung Hee, Jae-Joon Kim, Hyeon-Su Im, Hye Sook Han, In-Ho Kim, Dong-Hoe Koo, Jang Ho Cho i in. "Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06)." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): e16047-e16047. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16047.
Pełny tekst źródłaGuo, Weijian, Xiaowei Zhang, Yusheng Wang, Wen Zhang, Xin Liu, Wei Shen, Yifu He i in. "FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 4038. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4038.
Pełny tekst źródłaYu, Qianqian, Zhihuan Li, Xiaoqi Nie, Lu Wang, Chen Gong, Bo Liu, Xin Liao i in. "Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients". Journal of Cancer Treatment and Diagnosis 4, nr 2 (1.09.2020): 39–46. http://dx.doi.org/10.29245/2578-2967/2020/2.1182.
Pełny tekst źródłaPaulík, Adam, Jiří Grim i Stanislav Filip. "Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer". Acta Medica (Hradec Kralove, Czech Republic) 55, nr 4 (2012): 153–59. http://dx.doi.org/10.14712/18059694.2015.39.
Pełny tekst źródłaJanjigian, Yelena Yuriy, Laura H. Tang, Stephen Shibata, David Paul Kelsen, Michal Segal, Catherine Cheng, Gary K. Schwartz, L. Austin Doyle i Manish A. Shah. "A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e14586-e14586. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14586.
Pełny tekst źródłaLal, Rohit, James Dickson, David Cunningham, Ian Chau, Andrew R. Norman, Paul J. Ross, Clare Topham, Gary Middleton, Mark Hill i Jacqui Oates. "A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor—Resistant Advanced Colorectal Cancer". Journal of Clinical Oncology 22, nr 15 (1.08.2004): 3023–31. http://dx.doi.org/10.1200/jco.2004.01.005.
Pełny tekst źródłaAlmasmoum, Hussain. "Characterization of mucin 2 expression in colorectal cancer with and without chemotherapies, in vivo and in vitro study". Journal of Umm Al-Qura University for Medical Sciences 7, nr 1 (1.06.2021): 18–22. http://dx.doi.org/10.54940/ms28179947.
Pełny tekst źródłaGatzemeier, U. "Options for Treatment of Lung Cancer with Irinotecan". Oncology Research and Treatment 23, nr 4 (2000): 34–36. http://dx.doi.org/10.1159/000055055.
Pełny tekst źródłaDouillard, J.-Y. "Irinotecan: a new treatment in metastatic colorectal cancer". Journal of Oncology Pharmacy Practice 6, nr 3 (1.03.2000): 3–9. http://dx.doi.org/10.1191/107815500117842.
Pełny tekst źródłaTakano, Masashi, i Toru Sugiyama. "UGT1A1 polymorphisms in cancer: impact on irinotecan treatment". Pharmacogenomics and Personalized Medicine Volume10 (luty 2017): 61–68. http://dx.doi.org/10.2147/pgpm.s108656.
Pełny tekst źródłaDouillard, Jean-Yves. "Irinotecan: a new treatment in metastatic colorectal cancer". Journal of Oncology Pharmacy Practice 6, nr 3_suppl (wrzesień 2000): S3—S9. http://dx.doi.org/10.1177/107815520000600i301.
Pełny tekst źródłaHaller, Daniel G., Mace L. Rothenberg, Alfred O. Wong, Piotr M. Koralewski, Wilson H. Miller, Gyorgy Bodoky, Nassir Habboubi, Carlos Garay i Luis O. Olivatto. "Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma". Journal of Clinical Oncology 26, nr 28 (1.10.2008): 4544–50. http://dx.doi.org/10.1200/jco.2008.17.1249.
Pełny tekst źródłaKawakami, Takeshi, Nozomu Machida, Masahiro Kawahira, Sadayuki Kawai, Yosuke Kito, Yukio Yoshida, Satoshi Hamauchi i in. "Efficacy and safety of irinotecan monotherapy as third line treatment for advanced gastric cancer." Journal of Clinical Oncology 34, nr 4_suppl (1.02.2016): 113. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.113.
Pełny tekst źródłaHutchcraft, Megan L., Nan Lin, Shulin Zhang, Catherine Sears, Kyle Zacholski, Elizabeth A. Belcher, Eric B. Durbin i in. "Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes". Cancers 13, nr 18 (8.09.2021): 4524. http://dx.doi.org/10.3390/cancers13184524.
Pełny tekst źródłaIshii, Takahiro, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani i in. "Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer". Therapeutic Advances in Medical Oncology 12 (styczeń 2020): 175883592094237. http://dx.doi.org/10.1177/1758835920942377.
Pełny tekst źródłaScheithauer, Werner, Gabriela V. Kornek, Markus Raderer, Herbert Ulrich-Pur, Wolfgang Fiebiger, Claudia Gedlicka, Birgit Schüll i in. "Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer". Journal of Clinical Oncology 20, nr 1 (1.01.2002): 165–72. http://dx.doi.org/10.1200/jco.2002.20.1.165.
Pełny tekst źródłaYu, Kenneth H., Andrew Eugene Hendifar, Olatunji B. Alese, Amber Draper, Maen Abdelrahim, Ethan Burns, Gazala Naaz Khan i in. "A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e16733-e16733. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16733.
Pełny tekst źródłaSmith, Caleb J., Tanios S. Bekaii-Saab, Kathryn Cook, Rachel Eiring, Thorvardur Ragnar Halfdanarson, Mina Samir Erian Hanna, Zhaohui Jin i in. "Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer." Journal of Clinical Oncology 39, nr 3_suppl (20.01.2021): 402. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.402.
Pełny tekst źródłaKehrer, Diederik F. S., Ron H. J. Mathijssen, Jaap Verweij, Peter de Bruijn i Alex Sparreboom. "Modulation of Irinotecan Metabolism by Ketoconazole". Journal of Clinical Oncology 20, nr 14 (15.07.2002): 3122–29. http://dx.doi.org/10.1200/jco.2002.08.177.
Pełny tekst źródłaEbrahimpour, Mahnaz, Mahshid Mohammadian, Bagher Pourheydar, Zhino Moradi i Zhaleh Behrouzkia. "Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells". Journal of Lasers in Medical Sciences 13, nr 1 (28.02.2022): e9-e9. http://dx.doi.org/10.34172/jlms.2022.09.
Pełny tekst źródłaKim, George P., Daniel J. Sargent, Michelle R. Mahoney, Kendrith M. Rowland, Philip A. Philip, Edith Mitchell, Abraham P. Mathews i in. "Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841". Journal of Clinical Oncology 27, nr 17 (10.06.2009): 2848–54. http://dx.doi.org/10.1200/jco.2008.20.4552.
Pełny tekst źródłaCockrum, Paul, Andy Surinach, Stella Arndorfer, Jim M. Koeller i George P. Kim. "National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: An analysis of inpatient (IP) and emergency room (ER) admissions." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e16739-e16739. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16739.
Pełny tekst źródłaKipps, Emma, Kate Young i Naureen Starling. "Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy". Therapeutic Advances in Medical Oncology 9, nr 3 (marzec 2017): 159–70. http://dx.doi.org/10.1177/1758834016688816.
Pełny tekst źródła